Boc-NH-PEG7-Tos

CAS No. 1292268-14-4

Boc-NH-PEG7-Tos ( t-Boc-N-Amido-PEG7-Tos )

Catalog No. M26926 CAS No. 1292268-14-4

Boc-NH-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 59 Get Quote
10MG 79 Get Quote
25MG 124 Get Quote
50MG 178 Get Quote
100MG 264 Get Quote
500MG 647 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Boc-NH-PEG7-Tos
  • Note
    Research use only, not for human use.
  • Brief Description
    Boc-NH-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • Description
    Boc-NH-PEG7-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • Synonyms
    t-Boc-N-Amido-PEG7-Tos
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Human carboxylesterase 2 (hCES2A)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1292268-14-4
  • Formula Weight
    579.7
  • Molecular Formula
    C26H45NO11S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cc1ccc(cc1)S(=O)(=O)OCCOCCOCCOCCOCCOCCOCCNC(=O)OC(C)(C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kinghorn AD, et al. Natural inhibitors of carcinogenesis. Planta Med. 2004 Aug;70(8):691-705.
molnova catalog
related products
  • Notoginsenoside L13

    Reference standards.

  • PKG drug G1

    PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.

  • Teriflunomide(b)

    Teriflunomide is the principal active metabolite of leflunomide?an approved therapy for rheumatoid arthritis and?multiple sclerosis.